

# World Journal of *Diabetes*

*World J Diabetes* 2024 April 15; 15(4): 575-796



**EDITORIAL**

- 575 Nε-carboxymethyl-lysine and inflammatory cytokines, markers and mediators of coronary artery disease progression in diabetes  
*Eiras S*
- 579 Non-pharmacological interventions for diabetic peripheral neuropathy: Are we winning the battle?  
*Blaibel D, Fernandez CJ, Pappachan JM*
- 586 Effect of bariatric surgery on metabolism in diabetes and obesity comorbidity: Insight from recent research  
*Tang HH, Wang D, Tang CC*
- 591 Application and management of continuous glucose monitoring in diabetic kidney disease  
*Zhang XM, Shen QQ*
- 598 Pancreatic surgery and tertiary pancreatitis services warrant provision for support from a specialist diabetes team  
*Mavroeidis VK, Knapton J, Saffioti F, Morganstein DL*

**REVIEW**

- 606 Role of renin-angiotensin system/angiotensin converting enzyme-2 mechanism and enhanced COVID-19 susceptibility in type 2 diabetes mellitus  
*Shukla AK, Awasthi K, Usman K, Banerjee M*

**MINIREVIEWS**

- 623 Are treatment options used for adult-onset type 2 diabetes mellitus (equally) available and effective for children and adolescents?  
*Krnic N, Sesa V, Mrzljak A, Berkovic MC*

**ORIGINAL ARTICLE****Retrospective Cohort Study**

- 629 Prevalence and risk factors of wound complications after transtibial amputation in patients with diabetic foot  
*Park YU, Eim SH, Seo YW*

**Retrospective Study**

- 638 Prevalence and risk factors of diabetes mellitus among elderly patients in the Lugu community  
*Zhao LZ, Li WM, Ma Y*

- 645 Influence of blood glucose fluctuations on chemotherapy efficacy and safety in type 2 diabetes mellitus patients complicated with lung carcinoma

*Fang TZ, Wu XQ, Zhao TQ, Wang SS, Fu GMZ, Wu QL, Zhou CW*

- 654 Construction and validation of a neovascular glaucoma nomogram in patients with diabetic retinopathy after pars plana vitrectomy

*Shi Y, Zhang YX, Jiao MF, Ren XJ, Hu BJ, Liu AH, Li XR*

### Clinical Trials Study

- 664 Effect of special types of bread with select herbal components on postprandial glucose levels in diabetic patients

*Gostiljac DM, Popovic SS, Dimitrijevic-Sreckovic V, Ilic SM, Jevtovic JA, Nikolic DM, Soldatovic IA*

### Observational Study

- 675 Examining the association between delay discounting, delay aversion and physical activity in Chinese adults with type-2 diabetes mellitus

*An YD, Ma GX, Cai XK, Yang Y, Wang F, Zhang ZL*

- 686 Correlation of periodontal inflamed surface area with glycated hemoglobin, interleukin-6 and lipoprotein(a) in type 2 diabetes with retinopathy

*Thazhe Poyil NJ, Vadakkekuttical RJ, Radhakrishnan C*

### Prospective Study

- 697 Association of age at diagnosis of diabetes with subsequent risk of age-related ocular diseases and vision acuity

*Ye ST, Shang XW, Huang Y, Zhu S, Zhu ZT, Zhang XL, Wang W, Tang SL, Ge ZY, Yang XH, He MG*

- 712 Associations between remnant cholesterol levels and mortality in patients with diabetes

*Pan D, Xu L, Zhang LX, Shi DZ, Guo M*

### Basic Study

- 724 Teneeligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome

*Zhang GL, Liu Y, Liu YF, Huang XT, Tao Y, Chen ZH, Lai HL*

- 735 Novel insights into immune-related genes associated with type 2 diabetes mellitus-related cognitive impairment

*Gao J, Zou Y, Lv XY, Chen L, Hou XG*

- 758 Long-term effects of gestational diabetes mellitus on the pancreas of female mouse offspring

*Muñoz-Islas E, Santiago-SanMartin ED, Mendoza-Sánchez E, Torres-Rodríguez HF, Ramírez-Quintanilla LY, Peters CM, Jiménez-Andrade JM*

- 769 Icarin accelerates bone regeneration by inducing osteogenesis-angiogenesis coupling in rats with type 1 diabetes mellitus

*Zheng S, Hu GY, Li JH, Zheng J, Li YK*

**META-ANALYSIS**

- 783** Application of three-dimensional speckle tracking technique in measuring left ventricular myocardial function in patients with diabetes

*Li Z, Qian Y, Fan CY, Huang Y*

**LETTER TO THE EDITOR**

- 793** Metabolic syndrome's new therapy: Supplement the gut microbiome

*Xu YW, Tian J, Song Y, Zhang BC, Wang J*

**ABOUT COVER**

Peer Review of *World Journal of Diabetes*, Da-Feng Liu, MD, Doctor, Professor, The First Ward of Internal Medicine, Public Health Clinical Centre of Chengdu, Chengdu 610061, Sichuan Province, China. ldf312@126.com

**AIMS AND SCOPE**

The primary aim of *World Journal of Diabetes* (*WJD*, *World J Diabetes*) is to provide scholars and readers from various fields of diabetes with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

*WJD* mainly publishes articles reporting research results and findings obtained in the field of diabetes and covering a wide range of topics including risk factors for diabetes, diabetes complications, experimental diabetes mellitus, type 1 diabetes mellitus, type 2 diabetes mellitus, gestational diabetes, diabetic angiopathies, diabetic cardiomyopathies, diabetic coma, diabetic ketoacidosis, diabetic nephropathies, diabetic neuropathies, Donohue syndrome, fetal macrosomia, and prediabetic state.

**INDEXING/ABSTRACTING**

The *WJD* is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, PubMed Central, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for *WJD* as 4.2; IF without journal self cites: 4.1; 5-year IF: 4.5; Journal Citation Indicator: 0.69; Ranking: 51 among 145 journals in endocrinology and metabolism; and Quartile category: Q2.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: *Yu-Xi Chen*; Production Department Director: *Xu Guo*; Cover Editor: *Jia-Ru Fan*.

**NAME OF JOURNAL**

*World Journal of Diabetes*

**ISSN**

ISSN 1948-9358 (online)

**LAUNCH DATE**

June 15, 2010

**FREQUENCY**

Monthly

**EDITORS-IN-CHIEF**

Lu Cai, Md. Shahidul Islam, Michael Horowitz

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/1948-9358/editorialboard.htm>

**PUBLICATION DATE**

April 15, 2024

**COPYRIGHT**

© 2024 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>

## Basic Study

## Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome

Gu-Lao Zhang, Yuan Liu, Yan-Feng Liu, Xian-Tao Huang, Yu Tao, Zhen-Huan Chen, Heng-Li Lai

**Specialty type:** Endocrinology and metabolism**Provenance and peer review:**

Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind**Peer-review report's scientific quality classification**Grade A (Excellent): 0  
Grade B (Very good): 0  
Grade C (Good): C, C, C  
Grade D (Fair): 0  
Grade E (Poor): 0**P-Reviewer:** Pappachan JM, United Kingdom; Soriano-Ursúa MA, Mexico**Received:** October 8, 2023**Peer-review started:** October 8, 2023**First decision:** December 6, 2023**Revised:** December 20, 2023**Accepted:** February 27, 2024**Article in press:** February 27, 2024**Published online:** April 15, 2024**Gu-Lao Zhang, Yuan Liu, Yan-Feng Liu, Xian-Tao Huang, Yu Tao, Zhen-Huan Chen, Heng-Li Lai,** Department of Cardiology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang 330000, Jiangxi Province, China**Corresponding author:** Heng-Li Lai, MD, Chief Physician, Department of Cardiology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Aiguo Road, Donghu District, Nanchang 330000, Jiangxi Province, China. [laihengli@163.com](mailto:laihengli@163.com)**Abstract****BACKGROUND**

Diabetic cardiomyopathy (DCM), which is a complication of diabetes, poses a great threat to public health. Recent studies have confirmed the role of NLRP3 (NOD-like receptor protein 3) activation in DCM development through the inflammatory response. Teneligliptin is an oral hypoglycemic dipeptidyl peptidase-IV inhibitor used to treat diabetes. Teneligliptin has recently been reported to have anti-inflammatory and protective effects on myocardial cells.

**AIM**

To examine the therapeutic effects of teneligliptin on DCM in diabetic mice.

**METHODS**

Streptozotocin was administered to induce diabetes in mice, followed by treatment with 30 mg/kg teneligliptin.

**RESULTS**

Marked increases in cardiomyocyte area and cardiac hypertrophy indicator heart weight/tibia length reductions in fractional shortening, ejection fraction, and heart rate; increases in creatine kinase-MB (CK-MB), aspartate transaminase (AST), and lactate dehydrogenase (LDH) levels; and upregulated NADPH oxidase 4 were observed in diabetic mice, all of which were significantly reversed by teneligliptin. Moreover, NLRP3 inflammasome activation and increased release of interleukin-1 $\beta$  in diabetic mice were inhibited by teneligliptin. Primary mouse cardiomyocytes were treated with high glucose (30 mmol/L) with or without teneligliptin (2.5 or 5  $\mu$ M) for 24 h. NLRP3 inflammasome activation. Increases in CK-MB, AST, and LDH levels in glucose-stimulated cardiomyocytes were markedly inhibited by teneligliptin, and AMP (p-adenosine 5'-monophosphate)-p-AMPK (activated protein kinase) levels were increased. Furthermore, the beneficial effects of teneligliptin on hyperglycaemia-induced cardiomyocytes were abo-

lished by the AMPK signaling inhibitor compound C.

## CONCLUSION

Overall, teligliptin mitigated DCM by mitigating activation of the NLRP3 inflammasome.

**Key Words:** Diabetic cardiomyopathy; Teligliptin; NLRP3; AMPK; Interleukin-1 $\beta$

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Teligliptin mitigated diabetic cardiomyopathy by mitigating the activation of NLRP3 (NOD-like receptor protein 3) inflammasome. Teligliptin reversal markedly increased cardiomyocyte area and heart weight/tibia length, reduced fractional shortening, ejection fraction, and heart rate, increased creatine kinase-MB (CK-MB), aspartate transaminase (AST), and lactate dehydrogenase (LDH) levels, and upregulated NADPH oxidase 4 in streptozotocin-induced diabetic mice. Teligliptin repressed activated NLRP3 inflammasome and increased CK-MB, AST, and LDH levels in glucose-stimulated cardiomyocytes, accompanied by an upregulation of phosphorylated-adenosine 5'-monophosphate and activated protein kinase.

**Citation:** Zhang GL, Liu Y, Liu YF, Huang XT, Tao Y, Chen ZH, Lai HL. Teligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome. *World J Diabetes* 2024; 15(4): 724-734


**URL:** <https://www.wjgnet.com/1948-9358/full/v15/i4/724.htm>

**DOI:** <https://dx.doi.org/10.4239/wjd.v15.i4.724>

## INTRODUCTION

With the rapid development of international society and the economy, living standards have improved qualitatively. However, the prevalence of diseases has greatly increased, and diabetes mellitus (DM) is common. According to the International Diabetes Federation, there are 8.75 million people with type 1 diabetes (T1D) worldwide, or 0.11% of the global population. 1.52 million (17.0%) patients were younger than 20 years of age, 5.56 million (64.0%) patients were between 20 and 59 years of age, and 1.67 million (19.9%) patients were 60 years of age or older. In 2022, there will be 530000 newly diagnosed cases of T1D in all age groups, of which 200000 will be under 20 years old[1], posing a threat to public health. As a complication of DM, diabetic cardiomyopathy (DCM) is a condition in which the heart has abnormal myocardial structure and function in the absence of coronary artery disease, severe valvular lesions, or other conventional cardiovascular factors. DCM is characterized by lipid accumulation in the heart, myocardial fibrosis, and an increased probability of myocardial cell death, leading to left ventricular remodeling, hypertrophy, and diastolic dysfunction, which, in turn, contributes to systolic dysfunction[2]. The pathophysiological mechanism of DCM is related to an abnormal glucose supply and lipid metabolism owing to increased oxidative stress (OS), cellular activation regulated by multiple inflammatory pathways, extracellular damage, pathological cardiac remodeling, and diastolic and systolic dysfunction induced by DM[3]. NLRP3 (NOD-like receptor protein 3) is an inflammasome found in both immune and nonimmune cells, such as macrophages, cardiomyocytes, and fibroblasts. NLRP3 is upregulated in multiple diseases, including DCM and atherosclerosis[4]. Activation of the NLRP3 inflammasome has been shown to participate in DCM and the death of cardiomyocytes. In response to a variety of pathological factors, the NLRP3 inflammasome, and the expression of downstream cytokines are triggered, leading to a cascade of inflammatory reactions and causing damage to myocardial cells[5]. Furthermore, NLRP3 activation correlates with reactive oxygen species (ROS) production. Under high glucose conditions, ROS levels are elevated, which is important for NLRP3 inflammasome activation. In addition, ROS activate the NLRP3 inflammasome mainly by forcing cytochrome C to enter the cytoplasm and bind to NLRP3. NLRP3 is inactivated by inhibiting ROS production, which alleviates hyperglycaemia-induced myocardial cell damage [6]. Therefore, NLRP3 is a critical target for treating DCM.

Teligliptin (Figure 1A) is an oral hypoglycemic dipeptidyl peptidase-IV inhibitor developed by Mitsubishi Pharmaceutical Company in Japan that is mainly used to treat type II diabetes. By suppressing the inactivation of glucagon-like peptide *in vivo* by selectively inhibiting the activity of DPP-IV, teligliptin promotes the production of insulin by islet cells and reduces the concentration of glucagon, thereby reducing blood glucose. Teligliptin is well tolerated and has a low incidence of adverse reactions[7,8]. Recently, teligliptin was shown to have a promising suppressive effect on inflammation[9] and OS[10]. Teligliptin has been used to treat T2DM patients with renal impairment, including those with end-stage renal disease. Moreover, teligliptin has cytoprotective effects on myocardial cells[11]. Our study examined the possible therapeutic effectiveness of teligliptin in DCM in diabetic mice.



**Figure 1** Teneligliptin ameliorated myocardial hypertrophy in streptozotocin-induced diabetic mice. A: Molecular structure of teneligliptin; B: Quantitative analysis of cardiomyocyte area; C: Heart weight/tibia length. <sup>a</sup> $P < 0.05$  vs control group; <sup>b</sup> $P < 0.05$  vs streptozotocin group,  $n = 8$ . STZ: Streptozotocin.

## MATERIALS AND METHODS

### Animal experiments

The streptozotocin (STZ) solution (S0130; Sigma-Aldrich, St Louis, MO, United States) was prepared with citric acid/sodium citrate buffer, and 55 mg/kg STZ was administered to C57BL/6 male mice by intraperitoneal injection for 5 consecutive days. One week later, blood was collected from the tail vein and fasting blood glucose levels were detected by a Roche blood glucose meter. The mouse model of DCM was considered successfully constructed if the fasting blood glucose level was higher than 16.7 mmol/L. The mice were divided into three groups: Vehicle, STZ, and teneligliptin (SML3077; Sigma-Aldrich). In the vehicle and STZ groups, normal mice and diabetic mice received oral doses of normal saline. In the teneligliptin group, diabetic mice were orally administered 30 mg/kg teneligliptin for 4 wk. This study was approved by the Ethics Committee of Jiangxi Provincial People's Hospital.

### Measurement of heart function

The mice were anesthetized by an intraperitoneal injection of sodium pentobarbital to maintain a heart rate of approximately 300 beats/min and then placed on a thermostatic heating plate connected to a high-resolution small animal ultrasonic apparatus (VisualSonics, Toronto, ON, Canada). The following parameters were recorded: End-systolic diameter (ESD) and end-systolic volume (ESV), end-diastolic diameter (EDD) and end-diastolic volume (EDV), and heart rate. Fractional shortening was calculated as  $(EDD - ESD) / EDD \times 100\%$ , and the ejection fraction was calculated as  $(EDV - ESV) / EDV \times 100\%$ .

### Detection of myocardial injury indicators and interleukin-1 $\beta$

The levels of creatine kinase-MB (CK-MB), aspartate transaminase (AST), lactate dehydrogenase (LDH), and interleukin (IL)-1 $\beta$  were detected by ELISA (R&D Systems, Minneapolis, MN, United States). The supernatant was collected and added to a 96-well plate and the standards were added. After incubation for 1.5 h, the conjugate solution was added to the wells, after which the plates were incubated for another 1.5 h. Next, tetramethylbenzidine solution (861510; Sigma-Aldrich) was added, followed by a 15 min of incubation. Finally, the stop solution was added to stop the reaction, after which the optical density was detected with a microplate reader (Molecular Devices, San Jose, CA, United States) at 450 nm.

### HE staining

The collected myocardium was rinsed with water for 2 h. After being dehydrated with different concentrations of ethanol, the tissues were dehydrated with xylene until transparent, embedded for 1 h and then sliced. After being heated, dewaxed, and hydrated, the sections were immersed in water and subsequently stained with hematoxylin aqueous reagent for 2–3 min. After being differentiated in hydrochloric acid ethanol, the sections were stained with the blue-returning reagent for several seconds. After being stained with eosin for 180 s, images were obtained using an inverted microscope (Nikon, Tokyo, Japan).

### Real-time PCR

Total RNA was extracted from tissues or cells with TRIzol reagent, after which the RNA concentration was quantified with an ultraviolet spectrophotometer (Hach, Loveland CO, United States). RNA was transcribed to cDNA using a cDNA synthesis kit (SolelyBio, China). Subsequently, PCR was performed by using an SYBR Premix Ex TaqII kit (Takara, Shiga, Japan), and gene expression was determined by using the  $2^{-\Delta\Delta Ct}$  method.

### Western blot analysis

Tissues or cells were lysed to extract total proteins, followed by quantification using the bicinchoninic acid assay method. The proteins were separated by 12% SDS-PAGE and subsequently transferred to PVDF membranes. After the membranes were blocked, primary antibodies against NADPH oxidase 4 (1:2000, 14347-1-AP; Proteintech, Rosemont, IL, United States), NLRP3 (1:2000, 14347-1-AP; Proteintech), caspase-1 (1:2000, 22915-1-AP; Proteintech), p-AMPK (1:1000, 4186; Cell

Signaling Technology, Danvers, MA, United States), and  $\beta$ -actin (4970; Cell Signaling Technology) were used. Then, secondary antibodies (1:2000, 7074, 7076; Cell Signaling Technology) were added. The bands were visualized with enhanced chemiluminescence solution for quantification.

### Primary cardiomyocyte culture

Immature mice (0–2 d of age) were disinfected by immersion in 75% alcohol for 1–2 m. Then, a small incision was made under the sternum with sterilized ophthalmic scissors, after which the heart was collected and was placed in a Petri dish with precooled Hanks solution. The heart was then cut into 1 mm–3 mm pieces with scissors on an ultraclean table, followed by the addition of 7 mL of 0.1% type II collagenase. The rubber plug was blocked, the sealing membrane was added, and cells were then placed in a 37 °C incubator for 10 m until the cells naturally precipitated. The supernatant was discarded, and the digestion was terminated by gently mixing the solution approximately 60 times with a pipettor for 15 m. Then, the cell suspension was transferred to high glucose Dulbecco's modified Eagle's medium. The cell suspension obtained from each digestion was mixed until the tissue block was completely digested. The supernatant was discarded after being centrifuged at 1000 × rpm for 10 m, and an appropriate amount of complete medium was subsequently mixed with a 100  $\mu$ m nylon screen and inoculated into the culture flask, which was subsequently cultured at 37 °C in a 5% carbon dioxide incubator. After 90 m, the supernatant was mostly purified, and the cardiomyocytes were transferred to another culture flask for further culture.

### Statistical analysis

The data are presented as the mean  $\pm$  SD and were analyzed using one-way analysis of variance with GraphPad Prism software 6.0 (La Jolla, CA, United States).  $P < 0.05$  was considered to indicate a statistically significant difference.

## RESULTS

### Teligliptin ameliorated myocardial hypertrophy in STZ-induced diabetic mice

WGA staining was used to detect myocardial hypertrophy. Cardiomyocyte area in STZ-treated mice increased from 203.6  $\mu$ m<sup>2</sup> to 287.5  $\mu$ m<sup>2</sup> and was markedly reduced to 216.7  $\mu$ m<sup>2</sup> by teligliptin (Figure 1B). Moreover, the heart weight/tibia length in STZ-treated mice increased from 6.4 mg/mm to 8.3 mg/mm and was decreased to 6.2 mg/mm by teligliptin (Figure 1C). Moreover, teligliptin alleviated myocardial hypertrophy.

### Teligliptin improved heart function in STZ-induced diabetic mice

HE staining (Figure 2A) showed that myocardial cells in the vehicle group had a normal morphology, complete structure, dense and regular arrangement, and uniform distribution of nuclei. However, myocardial cells in diabetic mice were hypertrophic with a fuzzy structure, disordered arrangement, and some fiber breakage. The morphological structures of myocardial cells in the teligliptin group were neat with relatively regular arrangements and improvements in hypertrophy and fiber breakage. The fractional shortening of diabetic mice decreased from 53.5% to 38.7% and was markedly increased to 49.6% by teligliptin (Figure 2B). Furthermore, the ejection fractions in the vehicle, STZ, and teligliptin groups were 87.6%, 73.5%, and 85.5%, respectively (Figure 2C). The heart rates of the diabetic mice decreased from 462.5 beats/min to 458.7 beats/minute and then increased to 468.3 beats/min in response to teligliptin (Figure 2D). The heart function of diabetic mice was improved by teligliptin.

### Teligliptin reduced the expression of myocardial injury indicators in STZ-induced diabetic mice

CK-MB levels in diabetic mice increased from 303.5 U/L to 888.8 U/L but were markedly reduced to 578.8 U/L by teligliptin (Figure 3A). Moreover, AST levels in the vehicle, STZ, and teligliptin groups were 176.3, 522.6, and 371.8 U/L, respectively (Figure 3B). LDH levels in diabetic mice increased from 262.7 U/L to 697.5 U/L and then decreased to 451.2 U/L in response to teligliptin (Figure 3C).

### Teligliptin reduced NOX4 levels in diabetic mice


NOX4 is a critical pathological factor in DCM[12]. The increase in NOX4 levels in diabetic mice was markedly inhibited by teligliptin (Figure 4).

### Teligliptin reduced activation of the NLRP3 inflammasome in the heart in diabetic mice


First, NLRP3 and caspase-1 were notably upregulated in diabetic mice but markedly decreased by teligliptin (Figure 5A and B). Moreover, IL-1 $\beta$  levels in diabetic mice increased from 2.5  $\mu$ mol/mg to 3.4  $\mu$ mol/mg protein and then decreased to 2.8  $\mu$ mol/mg protein in response to teligliptin (Figure 5C). The suppressive effect of teligliptin on the NLRP3 inflammasome in the heart was observed.

### Teligliptin prevented activation of the NLRP3 inflammasome in the heart and injury in cardiomyocytes


Primary mouse cardiomyocytes were extracted and treated with high glucose (30 mmol/L) with or without teligliptin (2.5, 5  $\mu$ M) for 24 h. NLRP3 and caspase-1 Levels in cardiomyocytes were markedly increased by 30 mmol/L glucose but were inhibited by 2.5 and 5  $\mu$ M teligliptin (Figure 6A). Moreover, IL-1 $\beta$  levels in the control, high glucose, 2.5  $\mu$ M teligliptin, and 5  $\mu$ M teligliptin groups were 1.5, 2.7, 2.1, and 1.8  $\mu$ mol/mg protein, respectively (Figure 6B). CK-MB levels increased from 98.8 U/L to 288.5 U/L in 30 mmol/L glucose-treated cardiomyocytes and then decreased to 205.6




**Figure 2 Teneigliptin improved heart function in streptozotocin-induced diabetic mice.** A: The results of HE staining, Scale bar = 50  $\mu$ m; B-D: Mice heart fractional shortening, ejection fraction, and heart rate was measured by echo. <sup>a</sup> $P < 0.05$  vs control group; <sup>b</sup> $P < 0.05$  vs streptozotocin group,  $n = 8$ . STZ: Streptozotocin.




**Figure 3 Teneigliptin reduced the expression of the myocardial injury indicators in streptozotocin-induced diabetic mice.** A: Creatine kinase-MB level; B: The aspartate transaminase level; C: The lactate dehydrogenase level. <sup>a</sup> $P < 0.05$  vs control group; <sup>b</sup> $P < 0.05$  vs streptozotocin group,  $n = 8$ . STZ: Streptozotocin; CK-MB: Creatine kinase-MB; AST: Aspartate transaminase; LDH: Lactate dehydrogenase.



**Figure 4 Teneigliptin reduced the expression of NOX4 in diabetic mice.** A: mRNA of NOX-4; B: Protein of NOX-4; C: Quantitative analysis of protein expression levels for panel B. <sup>a</sup> $P < 0.05$  vs control group; <sup>b</sup> $P < 0.05$  vs streptozotocin group,  $n = 8$ . STZ: Streptozotocin.



**Figure 5** Teneligliptin reduced activation of the cardiac NLRP3 inflammasome in the control and diabetic mice. A: NLRP3 and caspase-1 measured by Western blot assays; B: Quantitative analysis of protein expression levels for panel A; C: Production of interleukin-1β as measured by ELISA. <sup>a</sup>*P* < 0.05 vs control group; <sup>b</sup>*P* < 0.05 vs streptozotocin group, *n* = 8. STZ: Streptozotocin.




**Figure 6** Teneligliptin prevented activation of the cardiac NLRP3 inflammasome and injury in cardiomyocytes. Primary cardiomyocytes were treated with high glucose (30 mmol/L) with or without teneligliptin (2.5 or 5 μM) for 24 h. A: Expression of NLRP3 and caspase-1 were measured by western blot assays; B: Levels of IL-1β as measured by ELISA; C: Levels of creatine kinase-MB and aspartate transaminase level. <sup>a</sup>*P* < 0.05 vs control group; <sup>b</sup>*P* < 0.05 vs high glucose 30 mmol/L group; <sup>c</sup>*P* < 0.05 vs high glucose 0 mmol/L + teneligliptin 0 μM group; <sup>d</sup>*P* < 0.05 vs high glucose 30 mmol/L + teneligliptin 0 μM group, *n* = 5. CK-MB: Creatine kinase-MB; AST: Aspartate transaminase; IL: Interleukin.

and 155.7 U/L in response to 2.5 and 5 μM teneligliptin, respectively. Furthermore, AST levels in the control, high glucose, 2.5 μM teneligliptin, and 5 μM teneligliptin groups were 105.6, 223.9, 170.5, and 146.6 U/L, respectively (Figure 6C). The suppressive effect of teneligliptin on the NLRP3 inflammasome in cardiomyocytes was observed.

**Treatment with teneligliptin increased the phosphorylation of AMPK in cardiomyocytes under high glucose conditions**

AMPK signaling reportedly regulates the NLRP3 inflammasome[13]. The decrease in p-AMPK in cardiomyocytes was reversed by 30 mmol/L glucose and this effect was markedly reversed by 2.5 and 5 μM teneligliptin (Figure 7), suggesting that teneligliptin affected AMPK signaling.



**Figure 7 Teneligliptin increased the phosphorylation of AMPK against high glucose in cardiomyocytes.** Primary cardiomyocytes were treated with high glucose (30 mmol/L) with or without teneligliptin (2.5 or 5 μM) for 24 h. Levels of p-AMPK were measured by western blot assays. <sup>a</sup> $P < 0.05$  vs control group; <sup>b</sup> $P < 0.05$  vs high glucose 30 mmol/L + teneligliptin 0 μM group,  $n = 5$ .

### **Inhibiting AMPK abolished the beneficial effects of teneligliptin on hyperglycaemia-induced cardiomyocytes**

For verification, primary mouse cardiomyocytes were treated with high glucose (30 mmol/L) with or without teneligliptin (5 μM) and in the presence or absence of compound C (10 μM) for 24 h. First, the reduction in p-AMPK in 30 mmol/L glucose-treated cardiomyocytes was notably attenuated by teneligliptin, and this effect was reversed by compound C (Figure 8A). Furthermore, the increase in NLRP3 observed in 30 mmol/L glucose-treated cardiomyocytes was strongly reduced by teneligliptin but was elevated by compound C (Figure 8B). Moreover, CK-MB levels increased from 102.5 U/L to 297.6 U/L in 30 mmol/L glucose-treated cardiomyocytes and then greatly decreased to 162.3 U/L in response to teneligliptin. After the administration of compound C, CK-MB levels were reversed to 255.2 U/L. AST levels in the control, high glucose, teneligliptin, and teneligliptin+ compound C groups were 112.3, 235.6, 155.3, and 215.3 U/L, respectively (Figure 8C). The beneficial effects of teneligliptin on hyperglycaemia-induced cardiomyocytes were abolished by AMPK inhibition.


## **DISCUSSION**

Studies have shown that NLRP3 is activated during DCM development through the inflammatory response and that teneligliptin exerts anti-inflammatory and protective effects in myocardial cells. In this study, we established an STZ-induced diabetes model and found that teneligliptin significantly inhibited cardiac hypertrophy and reduced fractional shortening and the ejection fraction induced by diabetes. Additionally, teneligliptin significantly reversed diabetes-induced increases in CK-MB, AST, and LDH. In addition, activation of the NLRP3 inflammasome and the increased release of IL-1β in diabetic mice were inhibited by teneligliptin, which was accompanied by the upregulation of p-AMPK. The same results were obtained in primary mouse cardiomyocytes treated with high glucose.

Teneligliptin is a low-cost oral hypoglycemic dipeptidyl peptidase-IV inhibitor that is used for diabetes treatment. Singh *et al*[14] searched 13 eligible studies containing data on 15720 subjects and showed similar efficacy (or better) and safety of teneligliptin compared with other DPP4Is. The average cost per tablet of teneligliptin (20 mg) was markedly lower than that of sitagliptin, vildagliptin, or other commonly used DPP4Is. Teneligliptin has various effects on both cardiovascular disease and other disorders. Teneligliptin can improve vascular endothelial function by improving flow-mediated vascular dilatation through divergent actions, including changes in circulating endothelial progenitor cells[15]. Teneligliptin-induced vasodilation occurs *via* the activation of protein kinase G, SERCA pumps and protein kinase G channels[16]. A systematic review of 13 randomized controlled trials that enrolled 2853 patients showed that teneligliptin was an effective and safe therapeutic option for patients with T2DM as a monotherapy and add-on therapy[17].

Teneligliptin has recently been reported to have anti-inflammatory and protective effects on myocardial cells, and DPP4 inhibitors have been reported to be associated with mitochondrial metabolism. Notably, teneligliptin enhances SIRT1 protein expression and activity through USP22, a ubiquitin-specific peptidase. Activated SIRT1 prevents hyperglycaemia-induced PRDX3 acetylation by SIRT3, resulting in the inhibition of PRDX3 hyperoxidation and thereby enhancing mitochondrial antioxidant defense[18]. In rat cardiac microvascular endothelial cells, teneligliptin significantly ameliorated the reduction in mitochondrial membrane potential induced by hypoxia/reoxygenation, indicating that teneligliptin could affect mitochondrial function[19]. In 5/6-nephrectomized mice, indoxyl sulfate induced mitochondrial dysfunction by decreasing the expression of PGC-1α and inducing autophagy, as well as decreasing the mitochondrial membrane potential, and teneligliptin reversed this effect[20]. In summary, although teneligliptin has been reported to have anti-inflammatory and protective effects on myocardial cells, future studies should focus on its ability to improve mitochondrial metabolism.

NLRP3 is a NOD-like receptor sensor molecule[21] that belongs to the cytoplasmic NOD family of pattern recognition receptors. After being activated, NLRP3 undergoes self-oligomerization and assembles with ASC and the protease caspase-1 to form the NLRP3 inflammasome. This process results in the production of the active form of the caspase-1 p10/p20 splicer and induces the conversion of the proinflammatory cytokines IL-1β and IL-18 from their immature forms



**Figure 8 Inhibition of AMPK abolished the beneficial effects of teneligliptin against high glucose in cardiomyocytes.** Primary cardiomyocytes were treated with high glucose (30 mmol/L) with or without teneligliptin (5 μM) and compound C (10 μM). A: Levels of p-AMPK; B: The levels of NLRP3; C: Levels of creatine kinase-MB and aspartate transaminase level. <sup>a</sup>*P* < 0.05 vs control group; <sup>b</sup>*P* < 0.05 vs high glucose 30 mmol/L group; <sup>c</sup>*P* < 0.05 vs high glucose 30 mmol/L + teneligliptin 5 μM group, *n* = 5.

to their active forms, inducing an inflammatory response[22]. The NLRP3 inflammasome triggers a form of cell death known as pyroptosis. NLRP3 activation triggers the autocatalytic activation of caspase-1, which drives the cleavage of the gasdermin D protein to produce N'-segment protein fragments that bind to phospholipid proteins on the cell membrane, form holes, and release inflammatory factors. Subsequently, cells continue to expand until the membrane ruptures, which is the process of pyroptosis[23]. NLRP3 inhibition improves insulin sensitivity in obese mice, suggesting that NLRP3 may participate in metabolism-related diseases such as diabetes[24]. In addition, hyperglycemia reportedly activates NLRP3 inflammasome-mediated pyroptosis in myocardial cells, and knocking down NLRP3 in DCM rats reduces the inflammatory response in myocardial tissues, inhibits the occurrence of myocardial pyroptosis and myocardial interstitial fibrosis, and improves cardiac function[25,26]. These findings suggest that the NLRP3 inflammasome is involved in DCM development. In our study, DCM model mice were generated by STZ injection, and the results were verified by assessing myocardial hypertrophy, impaired heart function, and myocardial injury indicator production; these findings were consistent with previous studies[27,28]. Following the administration of teneligliptin, myocardial hypertrophy was alleviated, heart function was improved, and myocardial injury indices were reduced, suggesting that teneligliptin alleviated DCM in mice. Moreover, the NLRP3 inflammasome was activated in both DCM mice and primary mouse cardiomyocytes stimulated with 30 mmol/L glucose, which is consistent with the findings of Song *et al*[29] and Shi *et al*[30]. Following the administration of teneligliptin, NLRP3 inflammasome activity was inhibited in both DCM mice and primary mouse cardiomyocytes stimulated with 30 mmol/L glucose, suggesting that the effect of teneligliptin might be mediated by inhibition of the NLRP3 inflammasome.

This study showed that teneligliptin improved cardiac function in DCM *in vivo* and *in vitro* and exerted its effect through NLRP3. One shortcoming of this study is that the direct effect of NLRP3 was not verified by knocking down or overexpressing NLRP3. In addition, the effect of teneligliptin on NLRP3-induced autophagy will be examined in future studies.

AMPK regulates NLRP3 inflammasome activation through multiple pathways, such as mitochondrial homeostasis, endoplasmic reticulum stress, autophagy, and SIRT1 activation. p-AMPK/AMPK is an important sensor molecule that regulates bioenergy homeostasis and reduces the activation of NF-κB to control the inflammatory response mediated by the NLRP3 inflammasome[31]. A previous study showed that autophagy was induced, mitochondrial ROS production was reduced, and IL-1β secretion was inhibited by mTOR inhibitors[32]. Autophagy is facilitated by AMPK through the activation of ULK or inhibition of the mTOR pathway. Furthermore, NLRP3 inflammasome activity is negatively regulated by autophagy through different mechanisms[33]. In our study, AMPK signaling was inhibited in primary mouse cardiomyocytes stimulated with 30 mmol/L glucose, which is consistent with the findings of Yang *et al*[13]. The sup-

pressive effect of 30 mmol/L glucose on AMPK signaling was reversed by teneligliptin, suggesting that the AMPK pathway mediates the effects of teneligliptin. Moreover, the beneficial effects of teneligliptin on hyperglycaemia-induced cardiomyocytes were abolished by inhibiting AMPK, suggesting that the regulatory effect of teneligliptin on DCM was controlled by AMPK. In the future, the exact mechanism will be identified by treating diabetic mice with teneligliptin plus compound C. This study limitation study should be mentioned. The study did not determine how teneligliptin interfered with AMPK/NLRP3 signaling in cardiomyocytes. It has been reported that NLRP3 plays an important role in cardiomyocyte pyroptosis during DCM. Future studies will further explore the effect of teneligliptin on cardiomyocyte pyroptosis during DCM. LCZ696 is a dual inhibitor of the AT1 receptor and of neprilysin signaling, and it remains unclear whether the effect of LCZ696 is dependent on these two pathways. The role of neprilysin in endothelial cells is not well known.

In summary, in this study, we established an STZ-induced diabetes model and found that teneligliptin significantly inhibited cardiac hypertrophy and reduced fractional shortening and the ejection fraction induced by diabetes. Through animal *in vivo* and cell *in vitro* experiments, we found that teneligliptin can improve DCM through NLRP3 pathway, which take to us that cell pyroptosis plays an important role in the improvement of DCM by treatment with teneligliptin. Future study should performed by NLRP3 knocking down and overexpressing to verified its direct effect, which is the main limitations of this study.

## CONCLUSION

Overall, teneligliptin mitigated DCM by mitigating activation of the NLRP3 inflammasome, which suggests that in future clinical work, teneligliptin may treat diseases involving the NLRP3 pathway.

## ARTICLE HIGHLIGHTS

### Research background

Diabetic cardiomyopathy (DCM), which is a complication of diabetes, poses a great threat to public health. Recent studies have confirmed the role of NLRP3 (NOD-like receptor protein 3) activation in DCM development through the inflammatory response. Teneligliptin is an oral hypoglycemic dipeptidyl peptidase-IV inhibitor used to treat diabetes. Teneligliptin has recently been reported to have anti-inflammatory and protective effects on myocardial cells.

### Research motivation

This study examined the therapeutic effects of teneligliptin on DCM in diabetic mice.

### Research objectives

Teneligliptin improves DCM by means of NLRP3, providing a new target for teneligliptin in the treatment of DCM.

### Research methods

Streptozotocin (STZ) was administered to induce diabetes in mice, followed by treatment with 30 mg/kg teneligliptin. Small animal ultrasonic apparatus was used to measure mice heart function, The levels of creatine kinase-MB (CK-MB), aspartate transaminase (AST), lactate dehydrogenase (LDH), and interleukin (IL)-1 $\beta$  were detected by ELISA, cardiomyocytes areas were measured by HE staining, Real-time PCR was used to measure NOX-4 mRNA expression, western blot was used to measure NOX-4, NLRP3, caspase-1, AMPK, p-AMPK protein expression level, primary cardiomyocytes was isolated in neonatal mice. The data are presented as the mean  $\pm$  SD and were analyzed using one-way analysis of variance with GraphPad Prism software 6.0.  $P < 0.05$  was considered to indicate a statistically significant difference.

### Research results

Marked increases in cardiomyocyte area and heart weight/tibia length; reductions in fractional shortening, ejection fraction, and heart rate; increases in CK-MB, AST, and LDH levels; and upregulated NADPH oxidase 4 were observed in diabetic mice, all of which were significantly reversed by teneligliptin. Moreover, NLRP3 inflammasome activation and increased release of IL-1 $\beta$  in diabetic mice were inhibited by teneligliptin. Primary mouse cardiomyocytes were treated with high glucose (30 mmol/L) with or without teneligliptin (2.5 or 5  $\mu$ M) for 24 h. NLRP3 inflammasome activation and the increases in CK-MB, AST, and LDH levels in glucose-stimulated cardiomyocytes were markedly inhibited by teneligliptin, and AMP (p-adenosine 5'-monophosphate)-p-AMPK (activated protein kinase) levels were increased. Furthermore, the beneficial effects of teneligliptin on hyperglycaemia-induced cardiomyocytes were abolished by the AMPK signaling inhibitor compound C.

### Research conclusions

Overall, teneligliptin mitigated DCM by mitigating activation of the NLRP3 inflammasome.

**Research perspectives**

Our study suggests that in future clinical work, tenelegliptin may treat diseases involving the NLRP3 pathway.

**FOOTNOTES**

**Co-corresponding authors:** Zhen-Huan Chen and Heng-Li Lai.

**Author contributions:** Zhang GL, Chen ZH, Lai HL designed the research study; Liu Y, Liu YF, Huang XT performed the research; Zhang GL, Chen ZH, Tao Y, and Lai HL analyzed the data and wrote the manuscript; all authors have read and approve the final manuscript. Lai HL and Chen ZH contributed equally to this work as co-corresponding authors. They made equally important contributions in the process of design, submission and revision, and interpreted all the research data.

**Supported by** National Natural Science Foundation of China, No. 82000276; and the Science and Technology Project of Jiangxi Provincial Health Commission, No. 202310005.

**Institutional animal care and use committee statement:** The study was reviewed and approved by the Jiangxi Provincial People's Hospital Institutional Review Board (Approval No. KT089).

**Conflict-of-interest statement:** All the Authors declare that they have no conflicts of interest related to this manuscript.

**Data sharing statement:** The data are available on reasonable request.

**ARRIVE guidelines statement:** The authors have read the ARRIVE Guidelines, and the manuscript was prepared and revised according to the ARRIVE Guidelines.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** China

**ORCID number:** Zhen-Huan Chen [0000-0001-5819-3392](https://orcid.org/0000-0001-5819-3392); Heng-Li Lai [0000-0002-5296-5432](https://orcid.org/0000-0002-5296-5432).

**S-Editor:** Lin C

**L-Editor:** Filipodia

**P-Editor:** Zhang YL

**REFERENCES**

- Sun H, Saedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Claude Mbanya J, Pavkov ME, Ramachandran A, Wild SH, James S, Herman WH, Zhang P, Bommer C, Kuo S, Boyko EJ, Magliano DJ. Erratum to "IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045" [Diabetes Res. Clin. Pract. 183 (2022) 109119]. *Diabetes Res Clin Pract* 2023; **204**: 110945 [PMID: [37863776](https://pubmed.ncbi.nlm.nih.gov/37863776/) DOI: [10.1016/j.diabres.2023.110945](https://doi.org/10.1016/j.diabres.2023.110945)]
- Japp AG, Gulati A, Cook SA, Cowie MR, Prasad SK. The Diagnosis and Evaluation of Dilated Cardiomyopathy. *J Am Coll Cardiol* 2016; **67**: 2996-3010 [PMID: [27339497](https://pubmed.ncbi.nlm.nih.gov/27339497/) DOI: [10.1016/j.jacc.2016.03.590](https://doi.org/10.1016/j.jacc.2016.03.590)]
- Tan Y, Zhang Z, Zheng C, Wintergerst KA, Keller BB, Cai L. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. *Nat Rev Cardiol* 2020; **17**: 585-607 [PMID: [32080423](https://pubmed.ncbi.nlm.nih.gov/32080423/) DOI: [10.1038/s41569-020-0339-2](https://doi.org/10.1038/s41569-020-0339-2)]
- Zeng C, Duan F, Hu J, Luo B, Huang B, Lou X, Sun X, Li H, Zhang X, Yin S, Tan H. NLRP3 inflammasome-mediated pyroptosis contributes to the pathogenesis of non-ischemic dilated cardiomyopathy. *Redox Biol* 2020; **34**: 101523 [PMID: [32273259](https://pubmed.ncbi.nlm.nih.gov/32273259/) DOI: [10.1016/j.redox.2020.101523](https://doi.org/10.1016/j.redox.2020.101523)]
- Zheng Y, Xu L, Dong N, Li F. NLRP3 inflammasome: The rising star in cardiovascular diseases. *Front Cardiovasc Med* 2022; **9**: 927061 [PMID: [36204568](https://pubmed.ncbi.nlm.nih.gov/36204568/) DOI: [10.3389/fcvm.2022.927061](https://doi.org/10.3389/fcvm.2022.927061)]
- Zhang H, Chen X, Zong B, Yuan H, Wang Z, Wei Y, Wang X, Liu G, Zhang J, Li S, Cheng G, Wang Y, Ma Y. Gypenosides improve diabetic cardiomyopathy by inhibiting ROS-mediated NLRP3 inflammasome activation. *J Cell Mol Med* 2018; **22**: 4437-4448 [PMID: [29993180](https://pubmed.ncbi.nlm.nih.gov/29993180/) DOI: [10.1111/jcmm.13743](https://doi.org/10.1111/jcmm.13743)]
- Scott LJ. Tenelegliptin: a review in type 2 diabetes. *Clin Drug Investig* 2015; **35**: 765-772 [PMID: [26475720](https://pubmed.ncbi.nlm.nih.gov/26475720/) DOI: [10.1007/s40261-015-0348-9](https://doi.org/10.1007/s40261-015-0348-9)]
- Sharma SK, Panneerselvam A, Singh KP, Parmar G, Gadge P, Swami OC. Tenelegliptin in management of type 2 diabetes mellitus. *Diabetes Metab Syndr Obes* 2016; **9**: 251-260 [PMID: [27574456](https://pubmed.ncbi.nlm.nih.gov/27574456/) DOI: [10.2147/DMSO.S106133](https://doi.org/10.2147/DMSO.S106133)]
- Liu X, Cao Y, Zhang Y, Sun B, Liang H. Tenelegliptin inhibits lipopolysaccharide-induced cytotoxicity and inflammation in dental pulp cells. *Int Immunopharmacol* 2019; **73**: 57-63 [PMID: [31078926](https://pubmed.ncbi.nlm.nih.gov/31078926/) DOI: [10.1016/j.intimp.2019.04.059](https://doi.org/10.1016/j.intimp.2019.04.059)]
- Sagara M, Suzuki K, Aoki C, Tanaka S, Taguchi I, Inoue T, Aso Y. Impact of tenelegliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study. *Cardiovasc Diabetol* 2016; **15**: 76 [PMID: [27184495](https://pubmed.ncbi.nlm.nih.gov/27184495/) DOI: [10.1186/s12933-016-0396-3](https://doi.org/10.1186/s12933-016-0396-3)]

- 11 Peng W, Rao D, Zhang M, Shi Y, Wu J, Nie G, Xia Q. Tenelegliptin prevents doxorubicin-induced inflammation and apoptosis in H9c2 cells. *Arch Biochem Biophys* 2020; **683**: 108238 [PMID: 31881187 DOI: 10.1016/j.abb.2019.108238]
- 12 Fan L, Xiao Q, Zhang L, Wang X, Huang Q, Li S, Zhao X, Li Z. CAPE-pNO(2) attenuates diabetic cardiomyopathy through the NOX4/NF-κB pathway in STZ-induced diabetic mice. *Biomed Pharmacother* 2018; **108**: 1640-1650 [PMID: 30372866 DOI: 10.1016/j.biopha.2018.10.026]
- 13 Yang F, Qin Y, Wang Y, Meng S, Xian H, Che H, Lv J, Li Y, Yu Y, Bai Y, Wang L. Metformin Inhibits the NLRP3 Inflammasome via AMPK/mTOR-dependent Effects in Diabetic Cardiomyopathy. *Int J Biol Sci* 2019; **15**: 1010-1019 [PMID: 31182921 DOI: 10.7150/ijbs.29680]
- 14 Singh H, Arora E, Narula S, Singla M, Otaal A, Sharma J. Finding the most cost-effective option from commonly used Dipeptidyl peptidase-4 inhibitors in India: a systematic study. *Expert Rev Endocrinol Metab* 2023; **18**: 347-354 [PMID: 37232153 DOI: 10.1080/17446651.2023.2216279]
- 15 Akashi N, Umemoto T, Yamada H, Fujiwara T, Yamamoto K, Taniguchi Y, Sakakura K, Wada H, Momomura SI, Fujita H. Tenelegliptin, a DPP-4 Inhibitor, Improves Vascular Endothelial Function via Divergent Actions Including Changes in Circulating Endothelial Progenitor Cells. *Diabetes Metab Syndr Obes* 2023; **16**: 1043-1054 [PMID: 37077576 DOI: 10.2147/DMSO.S403125]
- 16 Li H, An JR, Park M, Choi J, Heo R, Kang M, Mun SY, Zhuang W, Seo MS, Han ET, Han JH, Chun W, Park WS. The antidiabetic drug tenelegliptin induces vasodilation via activation of PKG, Kv channels, and SERCA pumps in aortic smooth muscle. *Eur J Pharmacol* 2022; **935**: 175305 [PMID: 36183856 DOI: 10.1016/j.ejphar.2022.175305]
- 17 Pelluri R, Kongara S, Nagasubramanian VR, Mahadevan S, Chimakurthy J. Systematic review and meta-analysis of tenelegliptin for treatment of type 2 diabetes. *J Endocrinol Invest* 2023; **46**: 855-867 [PMID: 36624224 DOI: 10.1007/s40618-023-02003-9]
- 18 Elumalai S, Karunakaran U, Moon JS, Won KC. High glucose-induced PRDX3 acetylation contributes to glucotoxicity in pancreatic β-cells: Prevention by Tenelegliptin. *Free Radic Biol Med* 2020; **160**: 618-629 [PMID: 32763411 DOI: 10.1016/j.freeradbiomed.2020.07.030]
- 19 Zhang Z, Jin X, Yang C, Li Y. Tenelegliptin protects against hypoxia/reoxygenation-induced endothelial cell injury. *Biomed Pharmacother* 2019; **109**: 468-474 [PMID: 30399583 DOI: 10.1016/j.biopha.2018.10.016]
- 20 Enoki Y, Watanabe H, Arake R, Fujimura R, Ishiodori K, Imafuku T, Nishida K, Sugimoto R, Nagao S, Miyamura S, Ishima Y, Tanaka M, Matsushita K, Komaba H, Fukagawa M, Otagiri M, Maruyama T. Potential therapeutic interventions for chronic kidney disease-associated sarcopenia via indoxyl sulfate-induced mitochondrial dysfunction. *J Cachexia Sarcopenia Muscle* 2017; **8**: 735-747 [PMID: 28608457 DOI: 10.1002/jcsm.12202]
- 21 Inoue M, Shinohara ML. The role of interferon-β in the treatment of multiple sclerosis and experimental autoimmune encephalomyelitis - in the perspective of inflammasomes. *Immunology* 2013; **139**: 11-18 [PMID: 23360426 DOI: 10.1111/imm.12081]
- 22 Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. *Nat Rev Immunol* 2019; **19**: 477-489 [PMID: 31036962 DOI: 10.1038/s41577-019-0165-0]
- 23 Mangan MSJ, Olhava EJ, Roush WR, Seidel HM, Glick GD, Latz E. Targeting the NLRP3 inflammasome in inflammatory diseases. *Nat Rev Drug Discov* 2018; **17**: 688 [PMID: 30116046 DOI: 10.1038/nrd.2018.149]
- 24 Shao BZ, Xu ZQ, Han BZ, Su DF, Liu C. NLRP3 inflammasome and its inhibitors: a review. *Front Pharmacol* 2015; **6**: 262 [PMID: 26594174 DOI: 10.3389/fphar.2015.00262]
- 25 Luo B, Huang F, Liu Y, Liang Y, Wei Z, Ke H, Zeng Z, Huang W, He Y. NLRP3 Inflammasome as a Molecular Marker in Diabetic Cardiomyopathy. *Front Physiol* 2017; **8**: 519 [PMID: 28790925 DOI: 10.3389/fphys.2017.00519]
- 26 Frangogiannis NG. The Extracellular Matrix in Ischemic and Nonischemic Heart Failure. *Circ Res* 2019; **125**: 117-146 [PMID: 31219741 DOI: 10.1161/CIRCRESAHA.119.311148]
- 27 Tong M, Saito T, Zhai P, Oka SI, Mizushima W, Nakamura M, Ikeda S, Shirakabe A, Sadoshima J. Mitophagy Is Essential for Maintaining Cardiac Function During High Fat Diet-Induced Diabetic Cardiomyopathy. *Circ Res* 2019; **124**: 1360-1371 [PMID: 30786833 DOI: 10.1161/CIRCRESAHA.118.314607]
- 28 Arow M, Waldman M, Yadin D, Nudelman V, Shainberg A, Abraham NG, Freimark D, Kornowski R, Aravot D, Hochhauser E, Arad M. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy. *Cardiovasc Diabetol* 2020; **19**: 7 [PMID: 31924211 DOI: 10.1186/s12933-019-0980-4]
- 29 Song S, Ding Y, Dai GL, Zhang Y, Xu MT, Shen JR, Chen TT, Chen Y, Meng GL. Sirtuin 3 deficiency exacerbates diabetic cardiomyopathy via necroptosis enhancement and NLRP3 activation. *Acta Pharmacol Sin* 2021; **42**: 230-241 [PMID: 32770173 DOI: 10.1038/s41401-020-0490-7]
- 30 Shi C, Wu L, Li L. LncRNA-MALAT 1 regulates cardiomyocyte scorching in diabetic cardiomyopathy by targeting NLRP3. *Cell Mol Biol (Noisy-le-grand)* 2022; **67**: 213-219 [PMID: 35818194 DOI: 10.14715/cmb/2021.67.6.28]
- 31 Cordero MD, Williams MR, Ryffel B. AMP-Activated Protein Kinase Regulation of the NLRP3 Inflammasome during Aging. *Trends Endocrinol Metab* 2018; **29**: 8-17 [PMID: 29150317 DOI: 10.1016/j.tem.2017.10.009]
- 32 Chen-Scarabelli C, Agrawal PR, Saravolatz L, Abuniat C, Scarabelli G, Stephanou A, Loomba L, Narula J, Scarabelli TM, Knight R. The role and modulation of autophagy in experimental models of myocardial ischemia-reperfusion injury. *J Geriatr Cardiol* 2014; **11**: 338-348 [PMID: 25593583 DOI: 10.11909/j.issn.1671-5411.2014.01.009]
- 33 Dong Y, Chen H, Gao J, Liu Y, Li J, Wang J. Molecular machinery and interplay of apoptosis and autophagy in coronary heart disease. *J Mol Cell Cardiol* 2019; **136**: 27-41 [PMID: 31505198 DOI: 10.1016/j.yjmcc.2019.09.001]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-3991568  
**E-mail:** [office@baishideng.com](mailto:office@baishideng.com)  
**Help Desk:** <https://www.f6publishing.com/helpdesk>  
<https://www.wjgnet.com>

